Incyte Corp (INCY)
- Sector
- Health Care
- Industry
- Biotechnology
- Last price
- $116.87
- As of
Kresmion compiles this page from INCY's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
INCYTE CORP (INCY): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-31.
See the full INCY dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for INCY on one page. Preview it with sample data, then open it live with a free account.
Preview the INCY dossierActive events for INCY
- high13F: funds added
3 tracked funds increased INCY this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +95% to INCY (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +173% to INCY (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 52% of INCY (2026Q2)
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +382% to INCY (2026Q2)
FREE, NO ACCOUNT
Every event on INCY, as it fires
You are seeing 5 of 37 events recorded on INCY since 2026-05-05.
The five above landed across 2 days. The other 32 were recorded on 11 other days. 19 of the 37 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in INCY (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 45337C102 · 2026Q2 | $398.1M | 0.55% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 45337C102 · 2026Q2 | $227.1M | 0.16% | , |
| Bridgewater Associates, LPCUSIP 45337C102 · 2026Q2 | $19.1M | 0.08% | , |
| CITADEL ADVISORS LLCCUSIP 45337C102 · 2026Q2 | $16.3M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 45337C102 · 2026Q2 | $9.4M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 45337C102 · 2026Q2 | $455K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, INCY
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
INCY against its peers
INCY's operating margin of 29.5% ranks in the 71st percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | INCY | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 5.1B USD | 1.9B USD | 87 | 18 |
| Gross margin | 92.8% | 85.2% | 70 | 14 |
| Operating margin | 29.5% | 10.5% | 71 | 18 |
| Net margin | 25.0% | 8.4% | 73 | 19 |
| Return on equity | 24.9% | 6.2% | 83 | 20 |
| P / E | 18.2x | 31.1x | 6 | 8 |
| 1 year | 27.5% | n/a | n/a | 1 |
Peers (23): UTHR, BNTX, INSM, ROIV, RPRX, ALNY, EXEL, ASND, GMAB, BIIB, NBIX, HALO, RVMD, BBIO, ONC, SMMT, BMRN, APGE.D, KYMR, CAI, ARGX, MDGL, NUVL.D. Left out: IVBXF (no annual filing), SBMFF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (INCY: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow INCY on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to INCY for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.